RMD — Resmed Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Resmed, fiscal year end - June 30th, USD millions except per share, conversion factor applied.

	C2019 June 30th	2020 June 30th	2021 June 30th	2022 June 30th	2023 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,607	2,957	3,197	3,578	4,223
Cost of Revenue
Gross Profit	1,494	1,718	1,844	2,024	2,356
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	2,042	2,162	2,293	2,578	3,071
Operating Profit	564	795	904	1,000	1,152
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	519	733	884	960	1,102
Provision for Income Taxes
Net Income After Taxes	411	622	475	779	898
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	405	622	475	779	898
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	405	622	475	779	898
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3.26	4.36	3.29	5.31	6.09
Dividends per Share